Status:

COMPLETED

Effects of Wobenzym® Plus in Healthy, Sportive People After Eccentric Exercise

Lead Sponsor:

Mucos Pharma GmbH & Co. KG

Conditions:

Muscle Injury

Muscle Soreness

Eligibility:

MALE

20-50 years

Phase:

PHASE4

Brief Summary

The aim of the current study is to investigate the therapeutic effect and especially the mode of action of Wobenzym® plus, an anti-inflammatory drug containing proteolytic enzymes, on exercise induced...

Eligibility Criteria

Inclusion

  • Subject is able and willing to sign the Informed Consent Form prior to screening evaluations
  • Subject is in good physical and mental health as established by medical history, physical examination, electrocardiogram, vital signs, results of biochemistry, haematology
  • Not anticipating any planned changes in lifestyle regarding activity and nutrition for the duration of the study
  • Non smoker
  • Men with strength training experience
  • Age: 20-50 years
  • BMI ≥20 kg/m2 and ≤ 32 kg/m2
  • medium concentric strength ability (150-300 Nm)

Exclusion

  • Relevant history or presence of any medical disorder, potentially interfering with this trial (e.g. volunteers having experienced any cardiovascular events such as infarction, angina, surgical endocoronary intervention, stroke or volunteers suffering from diabetes as well as acute or chronic injury of the musculoskeletal system, e.g. cruciate ligament rupture.
  • No intake of anti-inflammatory medication/ food supplements or intake of medications that directly affect parameters of muscle function or performance within 4 weeks prior to visit 1 or during the trial
  • Subjects not willing to abstain from intake of analgesic medication 24 hours prior to and during visit 1 and 2.
  • For this trial clinically relevant abnormal laboratory, vital signs or physical findings at screening
  • Known hypersensitivity to the study preparation or to single ingredients (e.g. Lactose intolerance)
  • Drug, alcohol and/or medication abuse
  • Known HIV-infection
  • Known acute or chronic hepatitis B and C infection
  • Participation in another clinical trial within the last 4 weeks and concurrent participation in another clinical trial
  • Blood donation within 4 weeks prior to trial start (visit 1) or during trial.

Key Trial Info

Start Date :

February 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2014

Estimated Enrollment :

69 Patients enrolled

Trial Details

Trial ID

NCT01845558

Start Date

February 1 2013

End Date

September 1 2014

Last Update

August 28 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Sportschule FFb Puch GmbH

Fürstenfeldbruck, Germany, 82256

Effects of Wobenzym® Plus in Healthy, Sportive People After Eccentric Exercise | DecenTrialz